Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Whites see higher use but similar outcomes of TAVR, TMVR compared to black, Hispanic patients

White patients are recommended for three of the most common structural heart disease interventions more often than their black and Hispanic counterparts, according to a recent study published in the Journal of the American Heart Association, but procedural outcomes are similar among the groups.

Thumbnail

Reports of burst balloons prompt Canadian recall of Sapien 3 Ultra

Reports of burst balloons with the Sapien 3 Ultra heart valve have resulted in an urgent safety notice from the manufacturer and a Canadian recall of the system.

FDA approves 4th-gen MitraClip for TMVR

Abbott’s fourth-generation MitraClip device was approved by the FDA July 15 to treat mitral regurgitation (MR) in a wider population of patients, the company announced this week.

Thumbnail

SAVR strips the average patient of nearly 2 years of life

Patients with aortic stenosis who undergo SAVR live on average 1.9 years less than the general population, according to a study published in the July issue of the Journal of the American College of Cardiology.

Thumbnail

Robotic catheter paves the way for combo valve procedures

A novel robotic catheter could simplify valve procedures while allowing cardiac surgeons to complete multiple interventions within the same time frame, according to research presented at TVT 2019 in Chicago.

Transcarotid access: The future of non-femoral TAVR?

Research presented at TVT 2019 in Chicago last week suggests a transcarotid approach to transcatheter aortic valve replacement is favorable for patients unable to tolerate femoral access, topping both transapical and transaortic approaches as the preferable route for alternate-access TAVR.  

Thumbnail

Why the next TAVR vs. SAVR trial should be in bicuspid AS patients

Physicians are facing a new issue as TAVR expands to younger populations—an increased incidence of bicuspid aortic stenosis.

‘Our patients are worth it’: Tackling the undertreatment of aortic stenosis in the US

The undertreatment of aortic stenosis in the U.S. is severe, driven by deep-rooted racial and sex disparities and a disconnect between patients and their clinicians.